Article Text
Statistics from Altmetric.com
Commentary on: Luymes CH, Poortvliet RKE, van Geloven N, et al. Deprescribing preventive cardiovascular medication in patients with predicted low cardiovascular disease risk in general practice - the ECSTATIC study: a cluster randomised non-inferiority trial. BMC Med. 2018;16(1):5.
Context
The prescription of cardiovascular drugs in primary prevention may be challenging due to the risk of adverse drug reactions overcoming the benefits in a population with low cardiovascular risk.1 The impact of drug deprescription in this context is still unknown.
Methods
This was a multicentric, open-label, cluster randomised controlled trial comparing the effect of the deprescription of cardiovascular drugs versus usual care.2 The trial included patients aged between 40 and 70 years with a low risk of cardiovascular events treated with antihypertensive drugs or lipid-lowering drugs for more than 1 year. The primary outcome was the difference in …
Footnotes
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Commissioned; internally peer reviewed.